Introduction {#sec1-2045894019854074}
============

Children and adults with pulmonary hypertension (PH) share some pathogenic and clinical features but the feasibility of diagnostic modalities differs between these age groups.^[@bibr1-2045894019854074][@bibr2-2045894019854074]--[@bibr3-2045894019854074]^ Echocardiography is used as a first-line tool to detect PH and to assess left ventricular (LV) and right ventricular (RV) dimensions and function.^[@bibr4-2045894019854074],[@bibr5-2045894019854074]^ In children and adults with significant RV pressure overload, the importance of biventricular size and function determination has increasingly been recognized.^[@bibr6-2045894019854074][@bibr7-2045894019854074][@bibr8-2045894019854074][@bibr9-2045894019854074][@bibr10-2045894019854074][@bibr11-2045894019854074][@bibr12-2045894019854074]--[@bibr13-2045894019854074]^ RV enlargement, due to pressure loading such as in PH, can lead to subsequent LV compression, which can easily be visualized by echocardiography.^[@bibr14-2045894019854074]^

Biventricular size and function variables and ventricular--ventricular interaction (VVI) are emerging in pediatric PH research.^[@bibr9-2045894019854074][@bibr10-2045894019854074][@bibr11-2045894019854074][@bibr12-2045894019854074]--[@bibr13-2045894019854074]^ As RV pressure overload progresses, direct or sequential RV--LV interaction leads to impaired LV filling. During direct interaction, the LV cavity is compressed owing to leftward bowing of the ventricular septum, causing impaired LV filling, reduced LV preload, and low cardiac output.^[@bibr9-2045894019854074][@bibr10-2045894019854074][@bibr11-2045894019854074][@bibr12-2045894019854074]--[@bibr13-2045894019854074]^ In the sequential mechanism, an increased RV afterload decreases RV output, with consequently decreased LV preload and output.^[@bibr17-2045894019854074]^ Here, we used echocardiographic imaging, together with hemodynamically obtained variables (i.e. indexed pulmonary vascular resistance \[PVRi\]) and disease severity classifications (New York Heart Association \[NYHA\] functional class \[FC\]/modified ROSS score) to evaluate biventricular dimensions or function in pediatric PH patients.

We hypothesized that VVI variables correlate with surrogate variables of clinical outcome in children with PH.

Materials and methods {#sec2-2045894019854074}
=====================

Study group {#sec3-2045894019854074}
-----------

Our study group consisted of 57 children and adolescents with PH; 26 patients had PH secondary to congenital heart disease (PH-CHD) (12 boys, 14 girls; median age = 6.6 years; age range = 116 days--18.0 years; body surface area \[BSA\] = 0.31--1.59 m^[@bibr2-2045894019854074]^); 12 patients had idiopathic (I)PAH (9 boys, 3 girls; median age = 14.4 years; age range = 309 days--17.9 years; BSA = 0.42--1.92 m^2^); and 19 patients had PH due to bronchopulmonary dysplasia (PH-BPD) (12 boys, 7 girls; median age = 1.0 year; age range = 104 days--7.6 years; BSA = 0.2--1.05 m^2^). The PH-CHD patients included patients with post-tricuspid left-to right shunts such as ventricular septal defect (VSD) and atrioventricular septal defects but no patients with isolated atrial septal defect (ASD). The respective CHDs were surgically repaired in all patients at a mean age of 6.1 months (age range = 0.45--14.3 months). None of our patients had Eisenmenger syndrome. The baseline characteristics and the type of congenital heart defects in our pediatric PH cohort are provided in [Table 1](#table1-2045894019854074){ref-type="table"}. Patients with severe atrioventricular valve regurgitation or conduit regurgitation were excluded from the study. Children and adolescents with left atrial hypertension or pulmonary venous obstruction were excluded from the study. Table 1.Demographic data of our 57 patients with PH.All PH patients Fulfilled inclusion criteria (n)57 Female (n (%))24 (42) Age at baseline (years) (range)5.7 (0.6--18.2) Body weight (kg) (range)20.8 (4.9--86.5) Body length (cm) (range)127 (50--187) BSA range (m^2^)0.2--1.92NYHA-FC/ROSS score I (n)18 II (n)27 III (n)12PH medication (n) Sildenafil (single)13 Bosentan4 Macitentan8 Bosentan, sildenafil (comb)10 Macitentan, sildenafil18 Selexipag (triple comb)4 Calcium antagonists3PAH-CHD (n = 26) TRV (m/s)3.9 (3.0--4.9) sPAP/sSAP (%)71 (39--102) mPAP (mmHg) (mean ± range)37 (27--55) PVRi (WU) (mean ± range)3.9 (2.2--15.3) TAPSE (mm)1.54 (1.21--1.74) PAAT (ms)75 ± 19Diagnosis (n) AVSD12 VSD10 PA with VSD4IPAH (n = 12) TRV (m/s)4.4 (3.3--5.6) sPAP/sSAP (%)88 (44--118) mPAP (mmHg) (mean ± range)47 (32--91) PVRi (WU) (mean ± range)8.9 (3.1--20.4) TAPSE (mm)1.32 (1.24--1.66) PAAT (ms)70 ± 16PH-BPD (n = 19) TRV (m/s)3.4 (2.9--4.3) sPAP/sSAP (%)62 (38--85) mPAP (mmHg) (mean ± range)35 (27--54) PVRi (WU) (mean ± range)5.6 (3.0--15.8) TAPSE (mm)1.12 (0.85--1.55) PAAT (ms)65 ± 16[^1][^2]

NYHA FC and the modified ROSS score^[@bibr18-2045894019854074],[@bibr19-2045894019854074]^ were determined by two pediatric cardiologists who were responsible for the daily medical care of the patients. At the time of enrolment, all patients were in a clinically stable condition without any changes in medications over the preceding four months. PH-targeted treatment was performed in accordance with the treatment algorithm for pediatric PH during the study period ([Table 1](#table1-2045894019854074){ref-type="table"}).

This study complies with all institutional guidelines related to patient confidentiality and research ethics including institutional review board approval of the Ethics Board of the Medical University of Graz.

Echocardiography {#sec4-2045894019854074}
----------------

An institutional study protocol for transthoracic echocardiography, including predefined two-dimensional (2D) variables and M-Mode variables, was designed and performed in all children with PH who visited our referral center. Echocardiograms were performed by two specifically trained cardiac sonographers (AG, MK), using commercially available echocardiographic system (Sonos iE33, Philips, Andover, MA, USA) using transducers of 5-1, 8-3, and 12-4 MHz depending on patient size and weight. Images were recorded digitally and later analyzed by one of the investigators using off-line software (Xcelera Echo; Philips Medical Systems, Eindhoven, The Netherlands). Echocardiographic images were considered to be of sufficient quality only if the entire endocardial surface of the cavities was clearly visualized in the apical four-chamber (4C) view at end-systole. All measurements were performed according to the pediatric guidelines of the American Society of Echocardiography (ASE).^[@bibr20-2045894019854074]^

### Imaging parameters of the left heart {#sec5-2045894019854074}

*LA dimension*: As per ASE guidelines, the measurements of LA size and area were performed at end-systole.^[@bibr20-2045894019854074]^ The area was obtained by tracing the endocardial border, excluding the pulmonary vein entrance.

*LV dimension*: The left ventricular internal dimensions at end-diastole (LVEDd) were measured in the apical 4C view at the level of the mitral valve leaflet tips obtained from 2D echocardiographic images. End-diastole was defined as measured at the end of the R wave.

*LVEF*: The biplane method of disks (modified Simpson method) as a 2D echocardiographic technique requiring area tracings of the LV cavity was used. This is the method usually recommended by the ASE for measuring LVEF.^[@bibr20-2045894019854074]^

### Imaging parameters of the right heart {#sec6-2045894019854074}

*RA dimension*: The RA area is traced at the end of ventricular systole from the lateral aspect of the tricuspid annulus to the septal aspect, excluding the area between the leaflets and annulus, following the RA endocardium, excluding the IVC and SVC and the RA appendage.

*RV dimension*: In the apical 4C view, the RV internal diameter at the base (RVEDd) was measured just apical to the tricuspid annulus at end-systole as a horizontal line from endocardium of the RV free wall to endocardium of the interventricular septum.

*Pulmonary artery acceleration time (PAAT)*: The PAAT was measured as the interval between the onset of ejection and the peak flow velocity, defined as the time from the onset to maximal velocity.^[@bibr21-2045894019854074]^ The PAAT is the interval in microseconds from the onset of ejection to the peak flow velocity and can be used for the estimation of RV pressure and sPAP.

*Systolic RV function*: The tricuspid annular plane systolic excursion (TAPSE) reflects the longitudinal excursion of the tricuspid annulus toward the apex, i.e. longitudinal RV systolic function, and is measured with M-mode in the apical 4C view.^[@bibr22-2045894019854074]^

### Imaging parameters of ventricular--ventricular interaction {#sec7-2045894019854074}

*RV/LV ratio*: The ratio of RV basal diameter of LV basal diameter measured from a parasternal short-axis image was calculated and measured three times. The RV/LV ratio was derived to combine a measure of RV size with septal shift secondary to elevated RV pressure.

*RV end-diastolic to LV end-diastolic diameter ratio*: The ratio of RVEDd to LVEDd was measured three times in the 4C view and their average was reported.

*RV end-diastolic to LV end-diastolic area ratio*: The ratio of RVED/LVED area was calculated and measured in the apical 4C view three times in end-diastole and their average was reported.

*RA/LA area ratio*: The RA/LA ratio was derived to combine a measure of RA size with possible interatrial septal shift secondary to elevated RA pressure. The ratio of RA to LA area was calculated and measured three times and their average was reported.

*LV end-systolic eccentricity index (LVEI)*: The LVEI was defined as the ratio of the anterior--inferior and septal--posterolateral cavity dimensions at the mid-ventricular level, in the parasternal short-axis view, determined at end-systole. The LVEI is the ratio of the minor axis of the LV parallel to the septum divided by the minor axis perpendicular to the septum.^[@bibr6-2045894019854074]^ The LVEI has limited power in postoperative CHD-PH patients due to an unpredictable effect of an e.g. VSD repair on the long-time performance of the interventricular septum. Of note, interpretation of LVEI is difficult or nearly impossible in patients with unrepaired CHD, e.g. children with a large, pressure-unrestrictive VSD.

Hemodynamic data {#sec8-2045894019854074}
----------------

Patients in whom right heart catheterization was performed within two months from the baseline echo-study were included in analysis to evaluate the correlation between echocardiography and invasively obtained hemodynamic measures, previously reported to confirm prognosis in pediatric PH, i.e. PVRi, mean PAP (mPAP), and sPAP/sSAP ratio.^[@bibr23-2045894019854074]^ Left-sided filling pressure and cardiac output data were obtained to rule out entities that can elevate PAP other than pulmonary vascular disorder, such as pulmonary venous hypertension. PH was defined as a mPAP ≥ 25 mmHg at rest, a pulmonary capillary wedge pressure (PCWP) \< 15 mmHg, and a pulmonary vascular resistance (PVR) ≥ 3 mm (WU.m^2^). Catheterization data are provided in [Table 1](#table1-2045894019854074){ref-type="table"}.

NYHA/modified ROSS score {#sec9-2045894019854074}
------------------------

The use of NYHA FC is limited in young children because of its subjective nature, although several pediatric studies have now shown NYHA FC to be a useful predictor of outcome also in pediatric PAH. An adapted functional classification for children (the modified ROSS score) has therefore been proposed and is now commonly used in children.^[@bibr18-2045894019854074],[@bibr19-2045894019854074]^

N-terminal-pro brain natriuretic peptide (NT-proBNP) {#sec10-2045894019854074}
----------------------------------------------------

NT-proBNP was analyzed within a routine blood sample. Therefore, blood was taken from the vein and was collected into lithium heparin tubes. The NT-proBNP assay was performed with Cobas 8000 from Roche Diagnostics (Mannheim, Germany).

Statistics {#sec11-2045894019854074}
----------

All data were measured from two well-trained observers. For data analysis, SPSS 24.0.0.0 (IBM Corp., Armonk, NY, USA) and the R package ggplot2 (version 3.1.0) was used. Data are presented as mean ± standard deviation (SD) or median and interquartile range (IQR). To account for systematic changes in the measured parameters in children and adolescents, values were z-transformed whenever possible. TAPSE were z-transformed using an age-specific formula^[@bibr18-2045894019854074]^) and RVED area, LA area, and RA were z-transformed using BSA-specific formulas.^[@bibr20-2045894019854074]^ Associations between age, sPAP, and PVRi with parameters of the left atrial, left ventricular, and ventricular interdependence were analyzed using Pearson\'s correlation coefficient (r) or Spearman\'s rank correlation (ρ). For each correlation, 95% confidence intervals (95% CI) were calculated using bootstrapping techniques. For visualizing, correlation coefficients and their 95% CI forest plots are given in the Supplemental Section, as Supplemental [Figs. 3](#fig3-2045894019854074){ref-type="fig"} and [4](#fig4-2045894019854074){ref-type="fig"}. Differences between WHO FC groups were analyzed and adjusted for patient\'s age using ANCOVA. Not normally distributed variables were rank transformed before performing ANCOVA. If the overall test showed a significant difference between groups, the significant results of the post-hoc analysis using Bonferroni adjustment is reported. Otherwise the overall test is reported. Fig. 1.(a) Association of the LVEF with the sPAP/sSAP ratio (r = −0.810, *P* \< 0.001) and (b) Association of the LVEF with the PVRi (ρ = −0.479, *P* = 0.001). LVEF, left ventricular ejection fraction; PVRi, indexed pulmonary vascular resistance; sPAP, systolic pulmonary arterial pressure, sSAP, systolic systemic arterial pressure. Fig. 2.(a) Association of the TAPSE with the sPAP/sSAP ratio and (b) Differences in TAPSE according to the NYHA FC/Ross Score. FC, functional class; sPAP, systolic pulmonary arterial pressure, sSAP, systolic systemic arterial pressure; TAPSE, tricuspid annular plane systolic excursion.Fig. 3.(a) Differences in RA/LA area ratio according to NYHA FC/Ross Score and (b) Differences in RV/LV dimension ratio according to NYHA FC/Ross Score. FC, functional class; LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle. Fig. 4.(a) Differences according to NYHA FC/Ross Score and the LVEF and (b) Differences according to NYHA FC/Ross Score and the LVEI. FC, functional class; LVEF, left ventricular ejection fraction; LVEI, left ventricular eccentricity index.

Results {#sec12-2045894019854074}
=======

Left heart parameters {#sec13-2045894019854074}
---------------------

LVEF negatively correlated with sPAP/sSAP ratio (r = −0.810, *P* \< 0.001) in the PH patients, with 41 of 57 patients (72%) still having a LVEF \> 60%. Increasing PVRi was associated with decreasing LVEF (ρ = −0.479, *P* = 0.001) and with increasing LVEI (ρ = 0.508, *P* \< 0.001) ([Fig. 1](#fig1-2045894019854074){ref-type="fig"}). No significant correlation between LA area versus sPAP/sSAP ratio (ρ = 0.046, *P* = 0.733) or versus PVRi (ρ = −0.120, *P* = 0.432) could be detected.

Right heart parameters {#sec14-2045894019854074}
----------------------

Higher RVED area values (ρ = 0.916, *P* \< 0.001) and RA area values (ρ = 0.921, *P* \< 0.001) were detected with an increasing disease severity (higher NYHA FC/ROSS score) in our PH patients. The systolic function parameter TAPSE decreased with an increasing sPAP/sSAP ratio (r = −0.392, *P* = 0.003), an increasing PVRi (ρ = −0.477, *P* \< 0.001), and an increasing age (ρ = 0.631, *P* \< 0.001). Age-specific TAPSE z-scores decreased with an increasing NYHA FC (FC I = −1.12 ± 1.62, FC II = −2.52 ± 1.51, FC III = −4.29 ± 1.58; FC I vs. FC III, *P* \< 0.001; FC II vs. FC III, *P* \< 0.005) in our patients ([Fig. 2](#fig2-2045894019854074){ref-type="fig"}).

Interdependence parameters {#sec15-2045894019854074}
--------------------------

An increasing sPAP/sSAP ratio was associated with an increasing RV/LV dimension ratio (r = 0.752, *P* \< 0.001), with an increasing RVED/LVED area ratio (r = 0.700, *P* \< 0.001), and with an increasing end-systolic RA/LA area ratio (r = 0.735, *P* \< 0.001). With an increasing LVEI, the sPAP/sSAP ratio increased (r = 0.636, *P* \< 0.001). An increasing PVRi was associated with an increasing ratio of the echocardiographically derived variables RVEDd/LVEDd (r = 0.459, *P* \< 0.005), RVED/LVED area (ρ = 0.471, *P* \< 0.001), and RV/LV dimension ratio (ρ = 0.399, *P* \< 0.01). The invasively measured parameter PVRi positively correlated with an increasing RA/LA area ratio (ρ = 0.513, *P* \< 0.001), (Supplemental [Fig. 1](#fig1-2045894019854074){ref-type="fig"}).

NYHA/modified ROSS score {#sec16-2045894019854074}
------------------------

The echocardiographically measured RA/LA area ratio increased with increasing NYHA FC in our pediatric PH patients (FC1 = 1.13 ± 0.13, FC2 = 1.15 ± 0.20, FC3 = 1.39 ± 0.32 \[FC I vs. FC III, *P* \< 0.02; FC II vs. FC III, *P* \< 0.02\]). Similarly, the RV/LV dimension ratio increased with higher NYHA FC (FC I = 0.87 \[0.79--1.03\], FC II = 0.96 \[0.85--1.03\], FC III = 1.18 \[1.02--1.30\] \[FC I vs. FC III, *P* \< 0.001\]) ([Fig. 3](#fig3-2045894019854074){ref-type="fig"}). Accordingly, increasing NYHA FC was associated with decreasing LVEF (FC I = 65.9 ± 3.7, FC II = 64.7 ± 3.6, FC III = 57.6 ± 6.8 \[FC I vs. FC III, *P* \< 0.001, FC II vs. FC III, *P* \< 0.001\]), while the LVEI (FC I = 1.29 ± 0.15, FC II = 1.45 ± 0.21, FC III = 1.64 ± 0.26 \[FC I vs. FC III, *P* \< 0.001, FC II vs. FC III, *P* \< 0.05\]) significantly increased ([Fig. 4](#fig4-2045894019854074){ref-type="fig"}).

Biomarker NT-proBNP {#sec17-2045894019854074}
-------------------

NT-proBNP values of our PH patients significantly increased with an increasing sPAP/sSAP ratio (ρ = 0.509, *P* \< 0.001). With increasing disease severity (NYHA FC), the NT-proBNP values significantly increased (FC I = 160 \[93--299\], FC II = 226 \[87--399\], FC III = 981 \[227--2060\] \[FC I vs. FC III, *P* \< 0.005, FC II vs. FC III, *P* \< 0.01\]) (Supplemental [Fig. 2](#fig2-2045894019854074){ref-type="fig"}).

Discussion {#sec18-2045894019854074}
==========

Herein, we investigated echocardiographic variables of biventricular dimensions/function, VVI, and their correlations with hemodynamic values, disease severity, and NT-proBNP values in a pediatric PH cohort.

Previous studies on the use of echocardiography in pediatric PH mostly focused on detection of elevated PAP as a means to either detect PH or to provide a non-invasive tool for follow-up in PH patients.^[@bibr15-2045894019854074],[@bibr16-2045894019854074],[@bibr25-2045894019854074]^ Measurements of left and right heart dimensions and functional variables are part of the pediatric guidelines of the ASE.^[@bibr20-2045894019854074]^ In addition, recently published pediatric nomograms for various chamber diameters showed that the most reproducible measurements of left heart and right heart variables can be derived from the apical 4C view.^[@bibr24-2045894019854074]^ The role of left heart size dimensions in diseases such as PH is currently increasingly recognized.^[@bibr26-2045894019854074],[@bibr27-2045894019854074]^ The physiology of VVIs is based on the in-series circulation and common pericardium, interventricular septum, and myocardial tracts running between the ventricles.^[@bibr28-2045894019854074]^ When an RV is enlarged due to pressure loading, such as in PH, it compresses the LV. The impact of the hypertensive RV is related to underfilling and dysfunction of the compressed LV, which reduces the LV ability to generate appropriate output.^[@bibr29-2045894019854074]^ Previous data on adult IPAH patients suggested that LV mechanics are altered, due to VVIs.^[@bibr30-2045894019854074]^

In our pediatric PH cohort, we found that a decreasing LVEF (in patients with severe PH) is associated with an increasing sPAP/sSAP ratio and also with an (invasively determined) increasing PVRi. With increasing disease severity in our patients, the LVEF was found to be decreased. Usually, due to the underfilling and compression of the LV in suprasystemic PH, the end-systolic volume of the LV in adults is described to be often very small, making the measured LVEF normal or high normal, although the LV stroke is likely decreased. However, we find different association in our cohort probably because most of our patients had sub-systemic RV pressure and were postoperative CHD-PH patients. Similar to our pediatric findings, Driessen et al.^[@bibr31-2045894019854074]^ reported the more pronounced LV compression, the more distended and dysfunctional the RV becomes and the lower its transverse shortening due to leftward systolic septal shift gets.

In 100 children with PH, the RVEF as well as the LV stroke volume measured by cardiac MR have been shown to correlate with clinical status and prognosis in children with PH.^[@bibr11-2045894019854074]^ These findings underlie the clinically relevant concept of VVIs in PH. Smaller volumes of the left atrium were shown to be a marker of disease severity in adults, which are associated with higher PVRi, higher sPAP/sSAP ratio, and higher BNP.^[@bibr32-2045894019854074]^ It is under discussion whether the reduced LV dimensions in advanced PH are more a result of an imbalanced RV/LV ratio because of compression by a dilated high-pressure RV or whether these reduced LV dimensions could also be due to ventricular interdependence-related change of the LV structure.

The LVEI measures the LV lateral dimension as a ratio over the anterior--posterior dimension in the short axis and is used to evaluate LV compression for hemodynamic assessment in PH patients.^[@bibr33-2045894019854074]^ The end-systolic LVEI has been shown to be a useful variable of RV mechanics in infants with bronchopulmonary dysplasia and may be incorporated in routine protocols when there is a concern for PH in neonates.^[@bibr34-2045894019854074],[@bibr35-2045894019854074]^ The LVEI can help guide clinicians as to whether relief of RV pressure overload (e.g. due to new medications) is adequate. We found that our pediatric PH patients with increased LVEI values have significantly smaller LA areas (*P* = 0.001) and that the LVEI increased with an increasing sPAP/sSAP ratio and also with an increasing PVRi, showing that the degree of LV compression due to significant RV afterload can be visualized, at least in PH-CHD patients with an intact ventricular septum.

The RV/LV end-systolic diameter ratio, as a different VVI variable, is measured from a parasternal short-axis image at the LV papillary muscle level as the ratio of the anterior--posterior dimension of RV and LV diameters at end-systole. The RV/LV ratio has been shown to correlate well with invasive hemodynamic measures and to be higher in pediatric PH patients compared to controls.^[@bibr16-2045894019854074]^ In our pediatric PH cohort, the RV/LV ratio positively correlated with an increasing sPAP/sSAP ratio and with an increasing NYHA FC. This suggests that these VVI variables (RV/LV ratio and the LVEI) might be able to reflect the disease severity of PH also in children suffering from PH.

The systolic longitudinal RV function parameter TAPSE is vastly independent of heart rate (HR) and, thus, is especially useful in children^[@bibr18-2045894019854074]^ and accepted to assess systolic RV function in children with PH.^[@bibr21-2045894019854074]^ In this study, TAPSE decreased with an increasing sPAP/sSAP ratio and an increasing PVRi. TAPSE also decreased with increasing NYHA FC in our pediatric PH patients. Therefore, our findings are in line with a previous report showing a correlation between elevated sPAP and decreased TAPSE values in pediatric PH.^[@bibr21-2045894019854074]^

Recently, children with PH were investigated by three-dimensional (3D) echocardiography: the ratio of stroke volume/end-systolic volume, as a surrogate of RV-arterial coupling ratio, correlates with RV strain data and is a strong predictor of adverse clinical events in pediatric PH. Furthermore, 3D-measured RVEF and free wall RV strain were reported as outcome predictors in children with PH.^[@bibr10-2045894019854074],[@bibr36-2045894019854074]^

NT-proBNP, a surrogate marker of RA stretch, is a well-established biomarker used in adult patients with PAH,^[@bibr37-2045894019854074]^ while in pediatric PH experience is relatively limited.^[@bibr38-2045894019854074]^ Pediatricians have to consider changing normative values of NT-proBNP throughout childhood.^[@bibr39-2045894019854074]^ Nir et al.^[@bibr39-2045894019854074]^ have shown that the levels of NT-proBNP are highest in the first days of life and decrease thereafter. Ploegstra et al.^[@bibr6-2045894019854074]^ identified the NT-proBNP as a significant prognostic factor in pediatric PH. NT-proBNP was also found to be a useful biomarker for both respiratory exacerbations and mortality in pediatric PH patients.^[@bibr37-2045894019854074]^ In our PH children, the NT-proBNP values positively correlated with the sPAP/sSAP ratio and with increasing NYHA FC/modified ROSS score. Thus, our data further support the use of NT-proBNP as a prognostic marker in children with PH.

We here provide a comprehensive overview of echocardiographic biventricular dimension and function and VVI variables in our pediatric PH cohort. We show that these echocardiographic variables significantly correlate with disease severity (NYHA FC/modified ROSS score), NT-proBNP values, and hemodynamic values. Thus, we suggest that a significantly increased RV afterload causes RV volume loading, which may paradoxically reduce LVEF because of direct VVI.

Limitations {#sec19-2045894019854074}
-----------

The heterogeneity in a patient\'s diagnosis (IPAH, PH-BPD, PH-CHD) may limit the interpretation of the findings. It is important to note that even slight differences in the echocardiographic plan can result in substantial differences in area and diameter quantification.^[@bibr40-2045894019854074]^ From an imaging point of view, LVEF was calculated by the modified Simpson method that can be inaccurate in abnormally shaped ventricles. As the prognostic value of 6-min walking distance (6MWD) in young children is not clear, with a minority of children being able to perform a reliable 6-min walking test we did not include this parameter in our study. We think this is justified due to data of a pediatric registry, where 6MWD was available in only one-third of children in a global cohort.^[@bibr1-2045894019854074]^ Furthermore, we found an association between increased sPAP/SAP and lower LVEF values. It is well-known that, due to a relative reduction in end-systolic LV size, LVEF artificially increases in beginning PH. Therefore, our findings likely represent more advanced disease states with all patients already receiving PH-targeted medication. Further studies are required to validate our data and to evaluate other parameters such as strain parameters concerning biventricular dimensions and function as well as VVI variables in pediatric PH.
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[^1]: Values are presented as n or median (range) unless otherwise specified.

[^2]: AVSD, atrioventricular septal defect; BSA, body surface area; BPD, bronchopulmonary dysplasia; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; NYHA, New York Heart Association; PA, pulmonary atresia; PAAT, pulmonary artery acceleration time; PH-CHD, pulmonary hypertension secondary to congenital heart disease; PVRi, pulmonary vascular resistance indexed; RV, right ventricle; sPAP/sSAP, systolic pulmonary arterial pressure/systolic systemic arterial pressure; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion; TRV, tricuspid regurgitation velocity; VSD, ventricular septal defect; WU, Wood Units.
